MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 13:58:41 27/06/2024 BST | ||
| 16.38 EUR / 16.69 EUR | +1.44% |
|
| Current month | +11.72% | ||
| 1 month | +11.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 16.37 | +0.43% |
| 26/06/24 | 16.3 | +0.93% |
| 25/06/24 | 16.15 | -1.70% |
| 24/06/24 | 16.43 | +3.33% |
| 21/06/24 | 15.9 | -0.93% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 01:52 pm
More quotesStatic data
| Product type | Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MB4XFY |
| ISIN | DE000MB4XFY5 |
| Date issued | 28/03/2023 |
| Strike | 300.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.54 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.28 € |
|---|---|
| Lowest since issue | 3.89 € |
| Spread | 0.31 € |
| Spread % | 1.86% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Certificates
- Certificat
